Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes

Author(s): Gerasimos Siasos*, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula A. Paschou, Evangelos Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis, Dimitrios Tousoulis

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 46 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Concerns of elevated cardiovascular risk with some anti-diabetic medications warranted trials on the cardiovascular outcome to demonstrate cardiovascular safety of newly marketed anti-diabetic drugs. Although these trials were initially designed to evaluate safety, some of these demonstrated significant cardiovascular benefits.

Purpose of Review: We reviewed the cardiovascular and safety outcomes of novel antidiabetic agents in patients with type 2 diabetes and established cardiovascular disease or at high risk of it. We included the outcomes of safety trials, randomized controlled trials, meta-analysis, large cohort studies, and real-world data, which highlighted the cardiovascular profile of DPP-4is, GLP-1RAs and SGLT-2is.

Conclusion: Although DPP-4is demonstrated non-inferiority to placebo, gaining cardiovascular safety, as well market authorization, SGLT-2is and most of the GLP-1RAs have shown impressive cardiovascular benefits in patients with T2D and established CVD or at high risk of it. These favorable effects of novel antidiabetic agents on cardiovascular parameters provide novel therapeutic approaches in medical management, risk stratification and prevention.

Keywords: Antidiabetic agents, SGLT-2i, GLP1-RA, DPP-4i, cardiovascular disease, cardiovascular outcomes, cardiovascular safety, cardioprotection.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 46
Year: 2020
Published on: 30 December, 2020
Page: [5911 - 5932]
Pages: 22
DOI: 10.2174/1381612826666201109110107
Price: $65

Article Metrics

PDF: 77